This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Novus Biologicals
other brands :
IMGENEX
product type :
antibody
product name :
AUTS2 Antibody
catalog :
NBP1-32784
quantity :
100 ul
price :
449 USD
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, zebrafish
application :
western blot
product information
brand :
Novus
master code :
NBP1-32784
SKU :
NBP1-32784
product name :
AUTS2 Antibody
unit size :
100 ul
seo description :
The AUTS2 Antibody - BSA Free from Novus is a rabbit polyclonal antibody to AUTS2. This antibody reacts with human,mouse,zebrafish. The AUTS2 Antibody - BSA Free has been validated for the following applications: Western Blot.
target :
AUTS2
category :
Primary Antibodies
buffer :
PBS (pH 7), 20% Glycerol
clonality :
Polyclonal
conjugate :
Unconjugated
dilution :
Western Blot 1:500-1:3000
host :
Rabbit
immunogen :
Recombinant protein encompassing a sequence within the center region of human AUTS2. The exact sequence is proprietary.
isotype :
IgG
purity :
Antigen Affinity-purified
species :
Human,Mouse,Zebrafish
theoretical molecular weight :
139 kDa
gene symbol :
AUTS2
accessionNumbers :
Q8WXX7
applications :
Western Blot
USD :
449 USD
alt names :
autism susceptibility candidate 2, autism susceptibility gene 2 protein, autism-related protein 1, KIAA0442FBRSL2, MGC13140
storage :
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
company information

Novus Biologicals
10771 E Easter Ave
Centennial, CO 80112
Centennial, CO 80112
novus@novusbio.com
https://www.novusbio.com3037301950
headquarters: USA
Novus Biologicals licenses, manufactures, and markets antibodies to over 20,000 unique targets to support a wide array of research areas. Novus is built on honesty, collaboration and strong relationships and continues to provide quality tools that accelerate research. Every product is backed by our 100% guarantee.
questions and comments